BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 32335286)

  • 1. Cannabis sativa: Much more beyond Δ
    Alves P; Amaral C; Teixeira N; Correia-da-Silva G
    Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of cannabinoids in the treatment of epilepsy.
    Gaston TE; Friedman D
    Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
    Hill TD; Cascio MG; Romano B; Duncan M; Pertwee RG; Williams CM; Whalley BJ; Hill AJ
    Br J Pharmacol; 2013 Oct; 170(3):679-92. PubMed ID: 23902406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
    Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
    Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constituents of Cannabis Sativa.
    Rock EM; Parker LA
    Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
    Iannotti FA; Pagano E; Moriello AS; Alvino FG; Sorrentino NC; D'Orsi L; Gazzerro E; Capasso R; De Leonibus E; De Petrocellis L; Di Marzo V
    Br J Pharmacol; 2019 May; 176(10):1568-1584. PubMed ID: 30074247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and the pharmacodynamics of cannabinoids.
    Lucas CJ; Galettis P; Schneider J
    Br J Clin Pharmacol; 2018 Nov; 84(11):2477-2482. PubMed ID: 30001569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
    Deiana S; Watanabe A; Yamasaki Y; Amada N; Arthur M; Fleming S; Woodcock H; Dorward P; Pigliacampo B; Close S; Platt B; Riedel G
    Psychopharmacology (Berl); 2012 Feb; 219(3):859-73. PubMed ID: 21796370
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Pellati F; Borgonetti V; Brighenti V; Biagi M; Benvenuti S; Corsi L
    Biomed Res Int; 2018; 2018():1691428. PubMed ID: 30627539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
    Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
    Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cannabidiol and Δ
    Smith SA; Le GH; Teopiz KM; Kwan ATH; Rhee TG; Ho RC; Wu J; Cao B; Ceban F; McIntyre RS
    Drug Metab Rev; 2024; 56(2):164-174. PubMed ID: 38655747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
    Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
    Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Cannabidiol Safety: A Review.
    Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
    Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valorization of CBD-hemp through distillation to provide essential oil and improved cannabinoids profile.
    Zheljazkov VD; Maggi F
    Sci Rep; 2021 Oct; 11(1):19890. PubMed ID: 34615971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ
    Piscitelli F; Pagano E; Lauritano A; Izzo AA; Di Marzo V
    Anal Chem; 2017 Apr; 89(8):4749-4755. PubMed ID: 28343385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.